Company Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
2.56 ^USD	-7.91%		-5.19%	+100.00%

Mar. 21	Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 21	Regulus Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Number of employees: 30

Managers	Title	Age	Since
Joseph Hagan CEO	Chief Executive Officer	55	16-01-03
Preston Klassen PSD	President	55	23-06-21
Crispina Calsada DFI	Director of Finance/CFO	54	19-08-29
Claire S. Padgett CTO	Chief Tech/Sci/R&D Officer	-	22-11-28
Rekha Garg LAW	General Counsel	-	22-11-28
Amin Kamel PRN	Corporate Officer/Principal	-	22-06-01
Daniel Penksa AUD	Comptroller/Controller/Auditor	39	15-05-31
Christopher Aker LAW	General Counsel	63	11-05-18
Brian K. Campion PRN	Corporate Officer/Principal	-	20-06-30

Members of the board	Title	Age	Since
Pascale Witz BRD	Director/Board Member	57	17-05-31
David Baltimore BRD	Director/Board Member	86	08-12-31
William Rastetter BRD	Director/Board Member	75	13-03-31
Stelios Papadopoulos CHM	Chairman	74	07-12-31
Jake Nunn BRD	Director/Board Member	54	19-06-10
Alice S. Huang BRD	Director/Board Member	85	21-01-25
Hugh Rosen BRD	Director/Board Member	64	16-06-01
Joseph Hagan CEO	Chief Executive Officer	55	16-01-03
Preston Klassen PSD	President	55	23-06-21
Kathryn J. Collier BRD	Director/Board Member	56	18-04-16

	Vote	Quantity	Free-Float	Total Float
Stock A	0	3,725,720	0	96.25 %
Stock B	0	258,707	0
Stock C	0	1,330,832	0
Stock D	1	65,465,251	64,540,836 ( 98.59 %)
Stock E	0	256,700	0

Name	Equities	%	Valuation
RA Capital Management LP 9.547 %	6,250,000	9.547 %	18 M $
Vivo Capital LLC 7.638 %	5,000,000	7.638 %	14 M $
Federated Global Investment Management Corp. 5.920 %	3,875,578	5.920 %	11 M $
Fidelity Management & Research Co. LLC 4.464 %	2,922,600	4.464 %	8 M $
Fidelity Management & Research Co. LLC 4.464 %	2,922,600	4.464 %	8 M $
NEA Management Co. LLC 2.972 %	1,945,579	2.972 %	6 M $
DAFNA Capital Management LLC 1.697 %	1,111,049	1.697 %	3 M $
Stelios Papadopoulos 1.495 %	978,388	1.495 %	3 M $
Deep Track Capital LP 1.191 %	779,924	1.191 %	2 M $
Vanguard Group, Inc. (Subfiler) 0.4375 %	286,431	0.4375 %	824 921 $

Name	Equities	%	Valuation
Sarissa Capital Management LP 12.87 %	423,162	12.87 %	1 M $
Pascale Witz 0.2059 %	6,770	0.2059 %	19 498 $

Name	Equities	%	Valuation
NEA Management Co. LLC 94.77 %	258,707	94.77 %	745 076 $

Name	Equities	%	Valuation
NEA Management Co. LLC 15.70 %	65,300	15.70 %	188 064 $

Regulus Therapeutics, Inc.

4224 Campus Point Court Suite 210

92121, San Diego

+858 202 6300

http://www.regulusrx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.78 USD

Average target price

7.25 USD

Spread / Average Target

+160.79%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
REGULUS THERAPEUTICS INC.	+100.00%	182M
VERTEX PHARMACEUTICALS INCORPORATED	-3.13%	103B
REGENERON PHARMACEUTICALS, INC.	+1.80%	96.56B
ARGENX SE	+1.72%	22.61B
BIONTECH SE	-18.19%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-25.68%	14.46B
NEUROCRINE BIOSCIENCES, INC.	+0.93%	13.25B
SAREPTA THERAPEUTICS, INC.	+21.63%	11.1B

Bio Therapeutic Drugs